Request an invite

Beqvez: how long were the pivotal tox studies?

fidanacogene elaparvovec · Factor IX
Longest pivotal study
104 weeks
“Single-Dose Intravenous Study of PF 06838435 in Monkeys with a 13- or 104-Week Observation Phase”
✓ VerifiedFDA pharmacology/toxicology review, p. 35Source ↗
Pivotal GLP studies
GLP single IV NHP study (30/90-day recovery, to day 542); 12-month mouse study; GLP 2-year NHP integration study
“A GLP Toxicity Study of -hFIX-Padua by Intravenous Infusion in Monkeys with a 30- or 90- day Recovery Period”
✓ VerifiedFDA pharmacology/toxicology review, p. 20Source ↗
Route in tox
Single intravenous infusion / slow bolus
“Route of Administration IV infusion (30 minute) via saphenous vein”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗

Same question, other gene therapies

Adstiladrin

nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)
22 (derived from the dosing and observation schedule)

Casgevy

exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)
20 weeks

Elevidys

delandistrogene moxeparvovec · Micro-dystrophin
24 weeks

Fayuvi

rebisufligene etisparvovec · SGSH (AAV9)
26 weeks

Genglycos

pariglasgene brecaparvovec · G6PC (AAV8)
26 weeks

Glybera

alipogene tiparvovec · LPL (AAV1)
26 weeks

Hemgenix

etranacogene dezaparvovec · Factor IX
26 weeks

Imlygic

talimogene laherparepvec · GM-CSF (oncolytic HSV-1)
12 (derived from the dosing and observation schedule)

Itvisma

onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)
52 weeks

Kebilidi

eladocagene exuparvovec · AADC
26 weeks

Kresladi

marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)
4 weeks

Lenmeldy

atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)
52 weeks

Luxturna

voretigene neparvovec · RPE65
31 weeks

Lyfgenia

lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
26 weeks

Otarmeni

lunsotogene parvec · OTOF (AAV, intracochlear)
27 weeks

Papzimeos

zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)
3 weeks

Roctavian

valoctocogene roxaparvovec · Factor VIII
26 weeks

Skysona

elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)
13 (derived from the dosing and observation schedule)

Strimvelis

autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)
16 weeks

Tudriqev

vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)
26 weeks

Vyjuvek

beremagene geperpavec · COL7A1 (HSV-1, topical)
9 (derived from the dosing and observation schedule)

Waskyra

etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)
64 weeks

Zevaskyn

prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)
8 weeks

Zolgensma

onasemnogene abeparvovec · SMN1
26 weeks

Zynteglo

betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
26 weeks

Summary across all 26 gene therapies →